Newswise — BOSTON – January 15, 2013 – About 33 percent of people with type 2 diabetes suffer kidney damage that progresses to end stage renal disease (ESRD), at which point they require either dialysis or kidney transplantation. Scientists have thought that this kidney disease is driven by damage to the glomeruli, blood vessels in the kidney, which spill the protein albumin into the urine. Current treatments targeting the resulting “albuminuria” do not prevent kidney failure.
However, a new study by Joslin Diabetes Center researchers that compares the metabolic fingerprints of patients who develop ESRD versus those who don’t has furnished new clues to the disease.
Published in Kidney International, the study is distinctive in examining the metabolism of patients while they were still healthy or in very early stages of the disease, and in the breadth of metabolic factors analyzed, says lead author Monika Niewczas, M.D., Ph.D. Dr. Niewczas is an instructor in medicine at Harvard Medical School and a research associate in the laboratory of Andrzej Krolewski, M.D., Ph.D., head of Joslin’s Section on Genetics and Epidemiology and senior author on the paper.
The analysis drew on the Joslin Kidney Study, selecting 40 patients from that study who progressed to ESRD and 40 patients who remained alive without ESRD during 8-12 years of follow-up. The Joslin researchers used global mass spectrometry to look for levels of approximately 2,400 metabolites (molecules produced during metabolism) in plasma samples from the patients.
Among the results, the scientists found 16 “uremic solute” molecules present in much higher levels in those who would go on to develop ESRD than those who would not develop the condition.
Uremic solutes are known to accumulate in plasma in the presence of kidney failure. Dr. Niewczas stresses that at the time of the sample collection kidney function was normal in the vast majority of the study subjects, suggesting that these molecules could either mark early stages of the disease or actually contribute to it.
Injury to the kidney’s tubular cells is one potential mechanism by which those metabolites might lead to kidney failure. “Many of the uremic solutes that were increased are handled by the tubules and are actively secreted by those cells,” Niewczas says. The high levels of these metabolites might be a sign of tubular injury, and they might also contribute to this injury.
Additionally, the researchers found a strong correlation between higher concentrations of myo-inositol, a metabolite involved in insulin signaling and in many other biological processes, and progression to ESRD.
“Metabolomics is an exciting new field, and this exploratory study is rich in very robust findings,” says Niewczas. “Until now, researchers generally were focusing their studies on uremic solutes just at the single-metabolite level, but here we used a very robust, high-throughput platform that screened a few thousand metabolites instead.”
“Alterations of metabolism in general are key to diabetes, and studies like this may have huge potential for unraveling new pathways which will lead to developing new drugs and new diagnostic tests,” she adds.
Earlier findings by the Krolewski lab may be already headed toward clinical diagnostic use. In 2012, researchers found that high concentrations of the proteins TNFR1 and TNFR2 in blood accurately predict the risk of kidney function loss in both type 1 and type 2 diabetes 10 years in advance. This work has been licensed to a firm that develops diagnostic tests, and a clinical test will be available in the near future, says Niewczas.
In addition to Niewczas and Krolewski, Joslin researchers Jan Skupien, Adam Smiles, William Walker, and James Warram made major contributions to the metabolomic study. Key outside colleagues included Subramaniam Pennathur of the University of Michigan, Timothy Meyer of Stanford School of Medicine, Gerard Berry of Boston Children’s Hospital and Harvard Medical School (HMS), and Joseph Bonventre of Brigham and Women’s Hospital and HMS. The study was supported by the National Institutes of Health.
* * *
About Joslin Diabetes Center
Joslin Diabetes Center, based in Boston, Massachusetts, undertakes diabetes research, clinical care, education and health and wellness programs on a global scale. Joslin is dedicated to ensuring that people with diabetes live long, healthy lives and offers real progress in preventing and curing diabetes. Joslin is an independent, nonprofit institution affiliated with Harvard Medical School, and is recognized worldwide for driving innovative solutions in diabetes prevention, research, education, and care.
Our mission is to prevent, treat and cure diabetes. Our vision is a world free of diabetes and its complications. For more information, visit www.joslin.org.
About Joslin ResearchJoslin Research comprises the most comprehensive and productive effort in diabetes research under one roof anywhere in the world. With 30‐plus faculty‐level investigators, Joslin researchers focus on unraveling the biological, biochemical and genetic processes that underlie the development of type 1 and type 2 diabetes and related complications.
Joslin research is highly innovative and imaginative, employing the newest tools in genetics, genomics and proteomics to identify abnormalities that may play a role in the development of diabetes and its complications. Joslin Clinic patients, and others with diabetes, have the option of participating in clinical trials at Joslin to help translate basic research into treatment innovations.
Joslin has one of the largest diabetes training programs in the world, educating 150 M.D. and Ph.D. researchers each year, many of whom go on to head diabetes initiatives at leading institutions all over the globe. For more information, visit www.joslinresearch.org.